Stella Pharma Corporation provided earnings guidance for the full year ending March 31, 2023. For the year, the company expects net sales of ¥220 million, operating loss of ¥850 million, loss of ¥823 million and loss per share of ¥28.55.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
385 JPY | -1.03% |
|
-0.52% | +35.09% |
13/02 | Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024 | CI |
2023 | Stella Pharma Corporation Provides Earnings Guidance for the Fiscal Year Ending March 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
+35.09% | 76.42M | |
+56.09% | 815B | |
+43.39% | 641B | |
-5.23% | 352B | |
+17.64% | 314B | |
+11.94% | 303B | |
+16.66% | 242B | |
+2.49% | 224B | |
+14.21% | 218B | |
+10.25% | 168B |
- Stock Market
- Equities
- 4888 Stock
- News Stella Pharma Corporation
- Stella Pharma Corporation Provides Earnings Guidance for the Full Year Ending March 31, 2023